Compare Danaher Corporation (DHR) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Rocket Lab USA Inc — how do they compare? Danaher Corporation trades at $201.7 (market cap $140.88B), while Rocket Lab USA Inc trades at $78.15 (market cap $49.24B). The key difference: Danaher Corporation is far larger — about 2.9× Rocket Lab USA Inc's market cap, and Danaher Corporation pays a 0.8% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| DHR | RKLB | |
|---|---|---|
Market Cap | $140.88B | $49.24B |
Sector | Health | Technology |
52-Week High | $242.05 | $150.23 |
52-Week Low | $161.91 | $39.48 |
Enterprise Value | $153.66B | $48.00B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
Rocket Lab (RKLB) trades at $76.73, down 5.32% over 24 hours, testing key support near $75 amid a bearish technical trend. The company reported Q1 2026 EPS of -$0.02, beating expectations, while revenue reached $601.80M in 2025 with a net loss of -$198.21M. Analyst sentiment remains bullish with a $119.10 consensus price target, supported by recent strategic moves like the Iridium acquisition announced July 13, 2026.
The outlook hinges on execution of growth initiatives and path to profitability, with risks including high cash burn and competitive pressures. Upside potential exists if operational efficiencies improve and satellite revenue scales, but investors face volatility from negative margins and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
